Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Patent
1993-03-01
1995-05-02
Daus, Donald G.
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
546 14, 546 23, 546155, 546269, 546156, 548561, 549 23, 549 60, 549214, 549283, 549285, 549404, A61K 3147
Patent
active
054121043
DESCRIPTION:
BRIEF SUMMARY
BACKGROUND
This invention relates to compounds having antiviral activity and to compounds having antihypertensive activity, pharmaceutical compositions containing them, and methods of treatment utilizing the compositions. In particular, this invention is related to compounds having antiviral activity against viruses of the herpes group, pharmaceutical compositions containing the compounds, and methods of treating infections with viruses of the herpes group using the pharmaceutical compositions.
There are four separate viruses of the herpes group which infect and cause disease in humans. These are (1) herpes simplex virus 1 and 2 (HSV-1 and HSV-2, respectively); (2) cytomegalovirus (CMV); (3) varicellazoster virus (VZ); and (4) Epstein-Barr virus (EB). Examples of diseases associated with herpes simplex virus infection include herpes labialis, genital herpes (herpes progenitalis), neonatal herpes, herpetic keratitis, eczema herpeticum, disseminated herpes, occupational herpes, herpetic gingivostomatitis, meningitis (aseptic), and encephalitis.
CMV is widespread in humans and numerous other mammals. The great majority of human CMV infections are subclinical; that is, the primary infection occurs with no signs or symptoms. An exception to this is a congenital infection which occasionally gives rise to cytomegalic inclusion body disease in infants. There is also a mononucleosis-like syndrome caused by the virus.
The great majority of serious cases due to CMV infection come from recurring infections in immuno-compromised patients, such as transplant patients and cancer patients. It has been estimated that silent CMV infections have occurred in a majority of humans by the time adulthood is reached.
VZ virus is associated with chicken-pox (varicella) and shingles (zoster) in humans.
EB virus is quite common and causes glandular fever; it is also believed to be responsible for genetic damage that leads to Burkitt's lymphoma.
Examples of drugs used to treat herpes infections include (1) IUDR (5'-iodo-2'-deoxyuridine); (2) Ara-C (1-[beta-D-arabinofuranosyl]-cytosine); (3) Ara-A (9-beta-D-arabinofuranosyladenine); and (4) Acyclovir (9-[(2-hydroxyethoxy)methyl]guanine). Also Haines et al. (U.S. Pat. No. 4,757,088 issued Jul. 12, 1988) disclose that lidocaine (2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide) is an antiviral agent in cell culture against HSV-1 and HSV-2, and is able to treat herpes virus infections of mammals. Haines et al. also disclose that lidocaine is particularly effective in the treatment of HSV oral and genital lesions in humans. According to Haines et al., the addition of pantothenic acid or its alcohol and salt forms, dexpanthenol and pantothenate respectively, to lidocaine or lidocaine hydrochloride significantly enhances the antiviral activity of those drugs.
Human hypertension is a disease of multiple etiologies. Drugs that act to control one form may not be effective in controlling another. Therefore, further drugs that can be useful in treating hypertension are desirable.
In view of current interest in the art for finding useful antihypertensive and useful antiviral agents, in particular, useful agents against herpes group viruses, any new compounds exhibiting antihypertensive activity or antiviral activity would be a welcome contribution to the art. This invention provides such a contribution.
SUMMARY OF THE INVENTION
This invention provides compounds which are useful as antiviral agents against DNA-containing viruses such as herpes group viruses. In particular, the compounds of this invention are useful against HSV-1 and HSV-2 and may also prove useful against CMV and EB.
The compounds of this invention are advantageous over known compounds because they inhibit early events in the viral replication. One embodiment of this invention provides antiviral compounds of Formula ##STR2## wherein: (A) X is selected from the group consisting of N-R.sup.3, O, S, and C(R.sup.3).sub.2 ; R.sup.20 is selected from the group consisting of --C(O)OR.sup.21, --OR.sup.21, --R.sup.21, and --N(R.sup.21).
REFERENCES:
patent: 2646355 (1953-07-01), Zweifel
patent: 2844594 (1958-07-01), Long
patent: 3025299 (1962-03-01), Pfister et al.
patent: 3088969 (1961-11-01), Pretka
patent: 3141893 (1964-07-01), Pfister et al.
patent: 3275658 (1966-09-01), Lednicer et al.
patent: 3515721 (1970-06-01), Ritter et al.
patent: 3960868 (1976-06-01), Ferrini et al.
patent: 4024275 (1977-05-01), Archer
patent: 4031099 (1977-06-01), Buckle et al.
patent: 4079066 (1978-03-01), Gardner
patent: 4107310 (1978-08-01), Allais et al.
patent: 4124587 (1978-11-01), Hardtmann
patent: 4168312 (1979-09-01), Schacht et al.
patent: 4187309 (1980-02-01), Hardtmann
patent: 4190659 (1980-02-01), Hardtmann
patent: 4363811 (1982-12-01), Evans
patent: 4526894 (1985-07-01), Enomoto et al.
patent: 4607039 (1986-08-01), Lecount et al.
patent: 4954518 (1990-09-01), Takano et al.
patent: 4963655 (1990-10-01), Kinder et al.
patent: 5064756 (1991-11-01), Carr et al.
patent: 5175151 (1992-12-01), Afonso et al.
patent: 5179093 (1993-01-01), Afonso et al.
patent: 5179107 (1993-01-01), Afonso et al.
patent: 5190956 (1993-03-01), Afonso et al.
patent: 5250547 (1993-10-01), Lochead
Briet et al., Chem. Abstr. vol. 87 entry 1843690 (1977).
Prima Fiore, Chem Abstr vol. 88, entry 37696Z (1976).
Prima Fiore et al. Atti Acad. Sc. Inst Bologna Cl. Sc. Fis. Rend, vol. 3 No. 2 pp. 95-98 (1976).
Derwent Abstract J90005-752-B (1990).
Derwent Abstract J89035-827-B (1989).
J. Chem. Soc. Perkin Trans. vol. 9, (Sep., 1989).
J. Chem. Soc. Perkin Trans. vol. 5, (May 1989), J. L. Gaston et. al., pp. 905-908.
Brownsart et. al., pp. 1679-1686.
Chem. Abstracts, vol. 114, (1991,) p. 767, entry 143242P.
Minker, Chem. Abstracts, vol. 86, (1977,) p. 36, entry 26053V.
Yoshizaki CA, Chem Abstr vol. 113, entry 211864Z (1990).
Schaeffer CA, Chem Abstr vol. 109, entry 170249Z (1988) abstracting DD 242806.
Derwent J 8 9035-827-B (1989).
Derwent J 90005-752-B (1990).
Clark et al. J Chem Soc. 438 (1964) pp. 438-445.
Afonso Adriano
Gentles Margaret J.
Weinstein Jay
Boxer Matthew
Daus Donald G.
Jeanette Henry C.
Nelson James R.
Schering Corporation
LandOfFree
Ester and alkoxy substituted benzopyrans does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ester and alkoxy substituted benzopyrans, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ester and alkoxy substituted benzopyrans will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1138343